oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2019 ( 35 )

2018 ( 219 )

2017 ( 227 )

2016 ( 357 )

Custom range...

Search Results: 1 - 10 of 204873 matches for " Kenneth P. Kodama "
All listed articles are free for downloading (OA Articles)
Page 1 /204873
Display every page Item
Anisotropy-based inclination correction for the Moenave Formation and Wingate Sandstone: implications for Colorado Plateau rotation
Kenneth P. Kodama
Frontiers in Earth Science , 2014, DOI: 10.3389/feart.2014.00015
Abstract: The ~201 Ma paleopole for North America (NA) at the Triassic-Jurassic boundary (TJB) is observed in two widely different locations; one paleopole is determined from the Mesozoic rift basins in eastern NA and the other from the Colorado Plateau (CP) in the southwestern United States. A large discrepancy in paleopole positions from these two localities has been attributed to large amounts of clockwise vertical axis rotation of the CP (>10°) combined with inclination shallowing of the paleomagnetism. The sedimentary inclinations of the eastern North American basins have been corrected for shallowing, but the CP inclinations have not. Simple vertical axis rotation of the CP is not enough to bring the two paleopoles into agreement. This study of the Moenave and Wingate Formations was conducted to correct CP inclinations using their high field isothermal remanent anisotropy. The Moenave Formation and laterally equivalent Wingate Sandstone, which span the TJB, were sampled in southern Utah and northern Arizona. Thermal demagnetization isolated a characteristic remanence carried by hematite from 20 sites. High field (5 T) isothermal remanent anisotropy indicated shallowing of the characteristic remanence with an average flattening factor of f = 0.69. An inclination-corrected paleopole for the Moenave and Wingate Formations is located at 62.5°N 69.9°E (α95 = 5.5°) and is shifted northward by 2.9° with respect to the uncorrected paleopole. When the inclination corrected paleopole is rotated counterclockwise 9.7° about an Euler pole local to the CP, it is statistically indistinguishable from the inclination-corrected paleopole from the eastern North American rift basins. Rotation of the uncorrected paleopole does not bring it into statistical agreement with rift basin paleopole, therefore an inclination shallowing correction is necessary to support rotation of the CP and bring the Moenave and Wingate paleopoles into agreement with the eastern North American basin paleopole.
Grand challenges in geomagnetism and paleomagnetism
Kenneth P. Kodama
Frontiers in Earth Science , 2013, DOI: 10.3389/feart.2013.00003
Abstract:
岩石磁组构可以揭示应变吗?——以华南地块早三叠世灰岩为例
韩玉林,谈晓冬,Kenneth,P.,Kodama
地球物理学报 , 2009, DOI: 10.3969/j.issn.0001-5733.2009.10.018
Abstract: 一般认为磁组构能有效地反映岩石所经历的应变特征.为了研究不同类型的磁组构和不同期次应变之间的关系,对来自华南地块两个地区的早三叠世灰岩样品进行了岩石磁学、磁组构以及应变特征的对比分析.来自湖北通山县的样品经历了三期构造变形,这为解析磁组构和多期次应变提供了理想的机会.岩石磁学结果显示携磁矿物主要为磁铁矿.磁化率各向异性(AMS)和非磁滞剩磁各向异性(AAR)结果显示其最小轴与层面垂直,最大轴和中间轴分布于层面内,反映了沉积和压实作用产生的应变,而后期构造应变在磁组构中没有体现.来自广东连县的样品发育有渗透性压溶缝面理和方解石脉,说明经历了构造应变.AMS结果没有显示占优势的组构方向.AAR结果显示三轴组构,其最大轴分布于最大应力方位,与构造应变特征吻合,最初的压实组构被构造应变组构所代替.上述结果表明:(1)AAR可以很好地反映渗透性应变的特征,而AMS有时会失效;(2)应变的尺度要小于样品的尺度,磁组构才能有效地反映应变.
Delayed Lumbar Artery Laceration and Symptomatic Retroperitoneal Hemorrhage Following IVC Filter Placement  [PDF]
Jennifer P. Montgomery, Kenneth J. Kolbeck
Open Journal of Radiology (OJRad) , 2015, DOI: 10.4236/ojrad.2015.54029
Abstract: Inferior vena cava filters are placed in selected patients to protect against potentially fatal pulmonary embolism. Generally, filter placement is regarded as a safe procedure although rare complications may arise. Recurrent thromboembolic events are the most common complications assoiated with inferior vena cava filters; however, there are multiple reports of filter fracture, migration, embolization, penetration and perforation. The aim of this report is to illustrate a serious potential complication of inferior vena cava filters. We report a rare case of symptomatic retroperitoneal hemorrhage occurring 3 weeks after filter placement treated successfully with selective arterial embolization of a lumbar artery laceration. This case serves to highlight the importance of retrieving filters when they are no longer beneficial.
Exon duplications in the ATP7A gene: Frequency and Transcriptional Behaviour
Mie Mogensen, Tina Skj?rringe, Hiroko Kodama, Kenneth Silver, Nina Horn, Lisbeth B M?ller
Orphanet Journal of Rare Diseases , 2011, DOI: 10.1186/1750-1172-6-73
Abstract: The ATP7A gene was screened for exon duplications using multiplex ligation-dependent probe amplification (MLPA). The expression level of ATP7A was investigated by real-time PCR and detailed analysis of the ATP7A mRNA was performed by RT-PCR followed by sequencing. In order to investigate whether the identified duplicated fragments originated from a single or from two different X-chromosomes, polymorphic markers located in the duplicated fragments were analyzed.Partial ATP7A gene duplication was identified in 20 unrelated patients including one patient with Occipital Horn Syndrome (OHS). Duplications in the ATP7A gene are estimated from our material to be the disease causing mutation in 4% of the Menkes disease patients. The duplicated regions consist of between 2 and 15 exons. In at least one of the cases, the duplication was due to an intra-chromosomal event. Characterization of the ATP7A mRNA transcripts in 11 patients revealed that the duplications were organized in tandem, in a head to tail direction. The reading frame was disrupted in all 11 cases. Small amounts of wild-type transcript were found in all patients as a result of exon-skipping events occurring in the duplicated regions. In the OHS patient with a duplication of exon 3 and 4, the duplicated out-of-frame transcript coexists with an almost equally represented wild-type transcript, presumably leading to the milder phenotype.In general, patients with duplication of only 2 exons exhibit a milder phenotype as compared to patients with duplication of more than 2 exons. This study provides insight into exon duplications in the ATP7A gene.Menkes disease (MD; MIM# 309400) is a multisystemic lethal disorder of impaired copper metabolism due to mutations in the X-linked ATP7A gene [1,2]. The disorder is transmitted in an X-linked recessive pattern. The ATP7A protein is a member of the P-type ATPase family that ensures the ATP-driven translocation of metal cations across cellular membranes. The protein plays a d
Hyperbaric oxygen therapy (1.5 ATA) in treating sports related TBI/CTE: two case reports
Kenneth P Stoller
Medical Gas Research , 2011, DOI: 10.1186/2045-9912-1-17
Abstract: Many more concussions were being reported in the National Football League (NFL) in the 2010 season. A total of 154 concussions, including practices and games, were reported from the start of the preseason through the eighth week of the 2010 regular season.That is an increase of 21 percent over the 127 concussions during the same span in 2009, and a 34 percent jump from the 115 reported through the eighth week of the 2008 season. (Associated Press, Dec 13, 2010)This either means better reporting is taking place or the game is getting more violent or some combination of the above. What hasn't changed is a lack of treatment. The lack of appropriate treatment for traumatic brain injury (TBI) and chronic traumatic encephalopathy (CTE) is not exclusive to the NFL by any means, but football players both young high school students and old retired NFL veterans are beginning to ask for Hyperbaric Oxygen Therapy (HBOT) to help them recover from their injuries.Is this a new fad for a therapy looking for a disease, after all if HBOT were efficacious in treating TBI/CTE wouldn't everyone in the medical profession know about it, and wouldn't there be chambers connected to every trauma center?HBOT has been treating brain injuries as far back as 1963, when it was first found effective in treating carbon monoxide poisoning [1,2]. Although the misconception that HBOT is only treating carboxy-hemoglobin persists to this day [3]. Brain injuries caused by decompression sickness and arterial gas emboli began being treated by HBOT using Navy Treatment Table six [4,5]. Delayed treatment (3 months) of an ischemic stroke with HBOT was reported by the US Navy in 1969 [6]. Subsequently successful treatment with HBOT for late treatment of a stroke, diabetic encephalopathy and near-drowning/global anoxia was also reported [7] with the additional evidence of pre and post functional brain imaging (SPECT). The medical literature continues to grow showing HBOT is efficacious in treated old carbon mon
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis
Kenneth P Johnson
Therapeutics and Clinical Risk Management , 2010, DOI: http://dx.doi.org/10.2147/TCRM.S6743
Abstract: ks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis Review (5264) Total Article Views Authors: Kenneth P Johnson Published Date April 2010 Volume 2010:6 Pages 153 - 172 DOI: http://dx.doi.org/10.2147/TCRM.S6743 Kenneth P Johnson Maryland Center for MS, Baltimore, Maryland, USA Abstract: An understanding of the risks, benefits, and relative value of glatiramer acetate (GA) in multiple sclerosis (MS) has been evolving based on recently completed head-to-head studies: REGARD (REbif vs Glatiramer Acetate in Relapsing MS Disease); BEYOND (Betaseron Efficacy Yielding Outcomes of a New Dose); and BECOME (BEtaseron vs COpaxone in Multiple Sclerosis with Triple-Dose Gadolinium and 3-Tesla MRI Endpoints). Outcomes in the primary endpoints of these trials showed no significant differences between GA and high-dose beta-interferons (IFNβs). Results of the PreCISe (Early GA Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis [CDMS] in Subjects Presenting With a Clinically Isolated Syndrome [CIS]) trial led to the US Food and Drug Administration approval of GA in patients with a CIS. Furthermore, the ongoing follow-up study to the original pivotal GA trial, now extending beyond 15 years, continues to support the safety of GA. Currently, GA and IFNβs are no longer the only immunomodulators available for MS. Introduction of the monoclonal antibody, natalizumab (Tysabri ; Biogen Idec, Inc., Cambridge, MA, USA) provides an alternative immunomodulator for MS and has changed the therapeutic landscape dramatically. However, the rare but serious cases of progressive multifocal leukoencephalopathy that have occurred with natalizumab have raised concerns among clinicians and patients about using this agent and some of the emerging agents. The potential risks and benefits of the emerging therapies (cladribine, alemtuzumab, rituximab, fingolimod, laquinimod, teriflunomide, and dimethyl fumarate) based on phase II/III trials, as well as their use for indications other than MS, will be presented. This review provides available data on GA, natalizumab, and the emerging agents to support new developments in our understanding of GA and how its long-standing role as a first-line therapy in MS will evolve within the increasingly complex MS therapeutic landscape.
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis
Kenneth P Johnson
Therapeutics and Clinical Risk Management , 2010,
Abstract: Kenneth P JohnsonMaryland Center for MS, Baltimore, Maryland, USAAbstract: An understanding of the risks, benefits, and relative value of glatiramer acetate (GA) in multiple sclerosis (MS) has been evolving based on recently completed head-to-head studies: REGARD (REbif vs Glatiramer Acetate in Relapsing MS Disease); BEYOND (Betaseron Efficacy Yielding Outcomes of a New Dose); and BECOME (BEtaseron vs COpaxone in Multiple Sclerosis with Triple-Dose Gadolinium and 3-Tesla MRI Endpoints). Outcomes in the primary endpoints of these trials showed no significant differences between GA and high-dose beta-interferons (IFNβs). Results of the PreCISe (Early GA Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis [CDMS] in Subjects Presenting With a Clinically Isolated Syndrome [CIS]) trial led to the US Food and Drug Administration approval of GA in patients with a CIS. Furthermore, the ongoing follow-up study to the original pivotal GA trial, now extending beyond 15 years, continues to support the safety of GA. Currently, GA and IFNβs are no longer the only immunomodulators available for MS. Introduction of the monoclonal antibody, natalizumab (Tysabri ; Biogen Idec, Inc., Cambridge, MA, USA) provides an alternative immunomodulator for MS and has changed the therapeutic landscape dramatically. However, the rare but serious cases of progressive multifocal leukoencephalopathy that have occurred with natalizumab have raised concerns among clinicians and patients about using this agent and some of the emerging agents. The potential risks and benefits of the emerging therapies (cladribine, alemtuzumab, rituximab, fingolimod, laquinimod, teriflunomide, and dimethyl fumarate) based on phase II/III trials, as well as their use for indications other than MS, will be presented. This review provides available data on GA, natalizumab, and the emerging agents to support new developments in our understanding of GA and how its long-standing role as a first-line therapy in MS will evolve within the increasingly complex MS therapeutic landscape.Keywords: annual relapse rate, alemtuzumab, cladribine, rituximab, fingolimod, teriflunomide, dimethyl fumarate, laquinimod, interferon
América Latina y el bloque del dólar en el siglo XXI. Dolarizar o no dolarizar?
Kenneth P. Jameson
Revista Economía , 2000,
Abstract: El artículo no presenta resumen.
A SUCCESSFUL EXPERIENCE OF IMMIGRANT INTEGRATION: EVIDENCE FROM UTAH
Kenneth P. JAMESON
Journal of Community Positive Practices , 2012,
Abstract: Immigration and the role of immigrants in U.S. society continue to be contested, though the effects of the 2012 Presidential election may lessen the national polarization. The experience of Utah both illustrates the tension in immigrant integration and offers insights into a successful attempt to address the issues. The Utah stance toward migrants has been and continues to be “blurred.” Several policies are quite welcoming, and the principles in the Utah Compact have provided a basis for measured discussion and have stopped new anti- immigrant legislation from being passed. The end result has been a relatively successful integration process that has melded the native attitudes toward immigrants, with the immigrants’ capabilities and efforts to integrate. So in contrast with other states, such as Arizona or Alabama, the mutual benefits that immigration offers have been largely realized. Most importantly, the immigrants, both documented and undocumented, have actively pursued integration with Utah society on a whole series of dimensions, from obtaining driver privilege cards to participating in political activity. They may be transnational actors, but they clearly exhibit a commitment to their new physical location. As such they have been quite active participants in brokering the boundaries between them and the wider Utah society. This, along with the evolution of policy and attitudes in the state, has led to very positive results in terms of their social mobility and health outcomes, exactly as we would expect from the history of a nation of immigrants.
Page 1 /204873
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.